A PHASE III, MULTICENTRE, RANDOMISED, DOUBLE BLIND, PARALLEL GROUP, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TOZORAKIMAB (MEDI3506) IN PATIENTS HOSPITALISED FOR VIRAL LUNG INFECTION REQUIRING SUPPLEMENTAL OXYGEN (TILIA)

Registry ID

D9185C00001

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

ASTRAZENECA CANADA INC

Start date

2023-11-21

Last update

2022-11-09

Conditions

• LUNG INJURY

View on source registry